H-89

Item no.	HY-15979-50mg
Manufacturer	MedChem Express
CASRN	127243-85-0
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 50 mg 5 mg
Category	Food Safety Allergenes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Chijiwa T, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990 Mar 25;265(9):5267-72.\|[2]Blazev R, et al. Effects of the PKA inhibitor H-89 on excitation-contraction coupling in skinned and intact skeletal muscle fibres. J Muscle Res Cell Motil. 2001;22(3):277-86.\|[3]Hosseini-Zare MS, et al. Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice. Eur J Pharmacol. 2011 Nov 30;670(2-3):464-70. Acta Biochim Biophys Sin (Shanghai). 2023 Nov 15;55(12):1855-1863.\|Adv Sci (Weinh). 2024 Jul 1:e2403640.\|Adv Sci (Weinh). 2025 Feb 7:e2413324.\|Am J Physiol Cell Physiol. 2024 Apr 22.\|Anim Nutr. 2022.\|Aquac Rep. 2024 Jun, 36, 102110.\|Aquac Res. 2020;00:1-10.\|Arch Biochem Biophys. 2020 Jul 15;687:108375.\|Biol Pharm Bull. 2024;47(6):1113-1118.\|Biomaterials. 2022: 121902\|Biomed Pharmacother. 2022 Feb 24;148:112728.\|BMC Biol. 2024 May 3;22(1):104.\|BMC Genomics. 2024 Apr 3;25(1):337.\|BMC Pharmacol Toxicol. 2023 Nov 20;24(1):63.\|Bone. 2020 Jun;135:115326.\|Brain Behav Immun. 2023 Nov 19:115:667-679.\|Brain Behav Immun. 2024 Mar 29:119:36-50.\|Cancer Cell Int. 2019 Sep 23;19:241.\|Cell Commun Signal. 2021 Oct 11;19(1):103.\|Cell Commun Signal. 2024 Jul 25;22(1):375.\|Cell Death Dis. 2024 Sep 30;15(9):699.\|Cell Metab. 2021 Mar 2;33(3):565-580.e7.\|Cell Metab. 2021 Sep 8;S1550-4131(21)00375-2.\|Cell Mol Immunol. 2023 Jan 5.\|Cell Rep. 2021 Sep 21;36(12):109726.\|Cell Rep. 2022 Oct 18;41(3):111498.\|Cells. 2023 Apr 6, 12(7), 1098.\|Chem Biol Interact. 2024 Sep 2:111224.\|Clin Transl Med. 2021 Jan 1.\|CNS Neurosci Ther. 2024 May;30(5):e14742.\|Ecotoxicol Environ Saf. 2021 Feb 25;214:112005.\|Endocrinology. 2023 Mar 17;bqad042.\|Evid-Based Compl Alt. Dec 12.\|Fitoterapia. 2022 Oct 15;105336.\|Free Radic Biol Med. 2024 May 31:222:72-84.\|Front Oncol. 2021 Oct 6;11:738300.\|Front Physiol. 05 January 2022.\|Front Physiol. 2021 Oct 28;12:770430.\|Genes Dis. 2020 Nov 21;8(6):867-881.\|Heart Surg Forum. 2024 Mar 17.\|Heliyon. 2024 Sep 19;10(19):e37958.\|Infect Immun. 2018 Dec 19;87(1). pii: e00508-1\|Int J Biol Sci. 2024 Aug 19;20(11):4476-4495.\|Int J Mol Sci. 2018 Oct 7;19(10). pii: E3053. \|Int J Mol Sci. 2022, 23(20), 12595.\|Int J Mol Sci. 2023 Jan 16;24(2):1771.\|Int J Mol Sci. 2023, 24(1), 320.\|iScience. 2021, 102820.\|iScience. 2025 Feb 21.\|iScience. 2025 Jan 21;28(2):111856.\|J Agric Food Chem. 2023 Oct 23.\|J Biol Chem. 2021 Apr 8;100644.\|J Bone Miner Metab. 2021 Apr 8.\|J Cell Mol Med. 2024 Apr;28(8):e18303.\|J Exp Clin Cancer Res. 2021 Apr 8;40(1):122.\|J Exp Clin Cancer Res. 2024 Apr 4;43(1):105.\|J Int Med Res. 2021 Mar;49(3):300060521999527.\|J Integr Agric. 2023 Feb 24.\|J Mater Sci Technol. 2023 Jun 30.\|J Neurophysiol. 2023 Dec 5.\|J Neurosci. 2016 Oct 12;36(41):10560-10573.\|J Orthop Surg Res. 2023 Nov 8;18(1):849.\|J Periodontol. 2019 Sep;90(9):1002-1013.\|Korean J Pain. 2023 Jul 1;36(3):335-346.\|Life Sci. 2025 Mar 10:123553.\|Microbiol Res. 2024 May 24:285:127779.\|Mol Brain. 2021 Jul 19;14(1):116.\|Mol Cell. 2023 Feb 22;S1097-2765(23)00102-8.\|Mol Neurobiol. 2024 Jun 10.\|Mol Reprod Dev. 2022 Apr 26.\|Nat Commun. 2022 Nov 4;13(1):6648.\|Neuro Oncol. 2024 Jan 5;26(1):137-152.\|Neurogastroenterol Motil. 2020 Oct;32(10):1514-1528.\|NPJ Biofilms Microbiomes. 2023 Feb 8;9(1):8.\|Nutr Diabetes. 2024 Jul 23;14(1):56.\|Nutrients. 2020 Jan 26;12(2):329.\|Phytomedicine. 2025 Jan 7.\|Proteome Sci. 2023 Oct 11;21(1):16.\|Psychoneuroendocrinology. 2020 Jul;117:104680.\|Res Sq. 2024 Jul 15.\|Res Sq. 2024 May 23.\|Research Square Preprint. 2020 Oct.\|Research Square Preprint. 2023 Sep 13.\|Royal Society of Chemistry. 2020, 11, 1132-1139.\|Sci Signal. 2020 Nov 24;13(659):eaax0273.\|Signal Transduct Target Ther. 2023 Aug 9;8(1):290.\|Small Methods. 2024 Oct 17:e2401144.\|Stem Cell Res Ther. 2020 Jan 3;11(1):2.\|Theranostics. 2021 Mar 24;11(12):5650-5674.\|Toxicol Lett. 2022 Feb 7;359:84-95.\|Acta Pharm Sin B. 2023 Dec 16.\|Adv Sci (Weinh). 2021 Oct 31;e2100808.\|Aging (Albany NY). 2018 Jul 24;10(7):1722-1744. \|Aging (Albany NY). 2020 Jun 9;12(11):10951-10968.\|Aging Cell. 2018 Jun;17(3):e12754. \|Biochem Biophys Res Commun. 2024 Feb 15, 149689.\|Biol Trace Elem Res. 2020 Sep 14. \|bioRxiv. 2024 Feb 8.\|bioRxiv. 2024 Oct 2:2024.09.30.615856.\|bioRxiv. 2024 Oct 22:2024.10.18.619152.\|Cell Commun Signal. 2022 Apr 12;20(1):52.\|Cell Death Dis. 2025 Jan 20;16(1):31.\|Elife. 2023 Jan 16;12:e81438.\|Environ Health (Wash). 2024 Aug 16;2(11):776-785.\|Eur J Pharmacol. 2024 Nov 6:985:177106.\|Exp Cell Res. 2021 Feb 15;399(2):112482.\|Exp Ther Med. January 31, 2022.\|FASEB J. 2020 Oct;34(10):13376-13395.\|Front Pharmacol. 2018 Apr 12;9:362. \|Harvard Medical School LINCS LIBRARY\|IJMPNP. 2019,5(1): 8-15.\|Int Immunopharmacol. 2024 Jan 12:128:111490.\|Int J Biol Sci. 2023 Apr 2,19.\|J Bone Miner Res. 2021 May 5.\|J Cell Mol Med. 2020 Apr;24(8):4736-4747.\|J Funct Foods. 2023 Dec, 111, 105902.\|Life Sci. 2022 May 28;120676.\|Nat Commun. 2023 May 31;14(1):3159.\|Nat Metab. 2024 Apr;6(4):708-723.\|PeerJ. October 25, 2022.\|Peptides. 2022 Jun 2;170824.\|Phytother Res. 2022 Nov 25.\|Prog Neurobiol. 2021 Mar 22;102041.\|Purinergic Signal. 2022 Jul 2.\|Reprod Sci. 2022 Oct 7.\|Research Square Preprint. 2024 Dec 04.\|Sci Total Environ. 2022 Oct 10;842:156854.\|Stem Cell Res Ther. 2020 May 19;11(1):182.\|Theranostics. 2021 Jan 1;11(6):2612-2633.\|Vet Microbiol. 2021, 109061.
Smiles	O=S(C1=CC=CC2=C1C=CN=C2)(NCCNC/C=C/C3=CC=C(Br)C=C3)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	127243-85-0
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Autophagy; PKA
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	446.36
Product Description	H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.
Manufacturer - Research Area	Neurological Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; Stem Cell/Wnt; TGF-beta/Smad
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15979-50mg-safety-datasheet.pdf